Universal Beteiligungs und Servicegesellschaft mbH Purchases New Position in Twist Bioscience Corporation (NASDAQ:TWST)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH has acquired 8,297 shares of Twist Bioscience Corporation valued at approximately $326,000 in the first quarter of 2023.
• Twist Bioscience reported a quarterly loss of ($0.66) earnings per share, missing analysts' estimates, while revenue for the quarter was $92.79 million, exceeding expectations.
• The stock has a market capitalization of $2.02 billion and recent analyst ratings indicate a consensus of "Moderate Buy" with an average price target of $50.40.

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Twist Bioscience Corporation (NASDAQ:TWST - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,297 shares of the company's stock, valued at approximately $326,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. First Light Asset Management LLC bought a new stake in shares of Twist Bioscience in the 4th quarter valued at $56,984,000. Marshall Wace LLP increased its stake in Twist Bioscience by 15,927.8% in the fourth quarter. Marshall Wace LLP now owns 846,107 shares of the company's stock valued at $39,319,000 after purchasing an additional 840,828 shares in the last quarter. Renaissance Technologies LLC increased its stake in Twist Bioscience by 86.0% in the fourth quarter. Renaissance Technologies LLC now owns 398,708 shares of the company's stock valued at $18,528,000 after purchasing an additional 184,398 shares in the last quarter. Norges Bank acquired a new position in shares of Twist Bioscience during the fourth quarter valued at about $7,584,000. Finally, D. E. Shaw & Co. Inc. boosted its position in shares of Twist Bioscience by 1,085.9% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 107,268 shares of the company's stock worth $4,985,000 after purchasing an additional 98,223 shares in the last quarter.

Insiders Place Their Bets

In other news, CEO Emily M. Leproust sold 1,678 shares of the business's stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $35.76, for a total value of $60,005.28. Following the completion of the sale, the chief executive officer owned 645,782 shares of the company's stock, valued at approximately $23,093,164.32. The trade was a 0.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Patrick John Finn sold 1,877 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $29.75, for a total value of $55,840.75. Following the completion of the transaction, the chief operating officer directly owned 240,783 shares in the company, valued at $7,163,294.25. This trade represents a 0.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 13,109 shares of company stock valued at $425,962 over the last three months. Insiders own 3.01% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on TWST shares. Robert W. Baird dropped their price target on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. The Goldman Sachs Group lowered their price target on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Guggenheim reiterated a "buy" rating and issued a $50.00 target price on shares of Twist Bioscience in a report on Tuesday, May 6th. JPMorgan Chase & Co. decreased their price objective on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. Finally, Barclays reduced their target price on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $50.40.

Twist Bioscience Price Performance

NASDAQ:TWST traded down $2.69 during midday trading on Tuesday, hitting $27.52. The company had a trading volume of 2,464,014 shares, compared to its average volume of 1,152,428. The stock's fifty day moving average price is $34.71 and its 200-day moving average price is $38.58. Twist Bioscience Corporation has a 52-week low of $27.12 and a 52-week high of $55.33. The company has a quick ratio of 4.24, a current ratio of 4.51 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $1.65 billion, a PE ratio of -18.98 and a beta of 2.36.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.10). The firm had revenue of $92.79 million during the quarter, compared to analysts' expectations of $92.00 million. Twist Bioscience had a negative return on equity of 29.38% and a negative net margin of 23.51%. As a group, research analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.